Treatment of Clinical and Resectable Stage IIIB–IV Cutaneous Melanoma

Clinical Scenario

This protocol is for patients with clinical and resectable stage IIIB–IV cutaneous melanoma — disease that is surgically operable yet carries meaningful systemic risk. In this population, a perioperative systemic strategy is supported by evidence and carries a strong recommendation.

Treatment Approach (Partial Overview)

The approach combines neoadjuvant immunotherapy before surgical resection with adjuvant immunotherapy after surgery — a perioperative strategy backed by evidence showing benefits outweigh harms.

The complete regimen, sequencing, and eligibility details are in the full protocol →

Instant Access to Structured Evidence-Based Regimens

References

Neoadjuvant pembrolizumab (maximum of three courses of 200 mg once every 3 weeks) followed by resection and adjuvant pembrolizumab (maximum of 15 courses of 200 mg once every 3 weeks) should be offered to patients with clinical and resectable stage IIIB-IV cutaneous melanoma (Type: Evidence based, benefits outweigh the harms; Evidence quality: Moderate; Strength of recommendation: Strong).

View source ↗